Subscribe

Infusion of Infliximab | Predicting a Reaction in Pediatric Patients

Purpose:

To determine if a pediatric patient receiving an infliximab infusion is likely to have a medically significant reaction.

Specialty:

Clinical Pharmacology & Toxicology

Objective:

risk factors, adverse effects

ICD-10:

T39.9

Description:

Infliximab is a chimeric antibody to tumor necrosis factor alpha that is used in patients with Crohn's disease and rheumatoid arthritis. Some patients develop an immune response following an infusion, resulting in an immediate or delayed reaction. Crandall and Mackner identified risk factors which could identify those patients at risk for a significant reaction. The authors are from Columbus Children's Hospital and the Ohio State University.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone